Chemotherapy after surgery for colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery within the last 12 weeks to remove your colorectal cancer and all liver spots, with scans showing no cancer remains
- You are between 18 and 75 years old
- Your blood counts are healthy enough (good white blood cells, red blood cells, and platelets)
- Your kidney and liver function are adequate to handle chemotherapy
- You have not had chemotherapy before, or if you did, it did not contain irinotecan and your last dose was more than 3 months ago
- You are in good enough health to tolerate treatment (able to care for yourself with minimal assistance)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy directly into the liver artery after surgery to remove liver tumors. It's for people with colorectal cancer that spread to the liver, who have a high chance of the cancer coming back.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Colorectal Cancer Liver Metastases (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.